ZNF384 and acute lymphoblastic leukemia: For both patients receiving chemotherapy alone and, for all the patients, among whom received allo-HSCT were censored at the time of transplantation, patients with ZNF384 fusions had both similar RFS rate and similar OS rate to B-other ALL patients with no ZNF384 fusions (RFS: P = 0.94 and 0.30; OS: P = 0.94 and 0.51).